Mylan once again defends King deal in face of Icahn stock buy PITTSBURGH Mylan Laboratories again reiterated its commitment to the estimated four (B) billion dollar acquisition of brand-name drug maker King Pharmaceuticals despite Wall Street financier Carl Icahn upping his stake in the company. 
Is this a piece of news regarding world politics, sports, business, or science and technology? 